We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

88 hedge funds and large institutions have $227M invested in Arbutus Biopharma in 2018 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 9

44% more capital invested

Capital invested by funds: $158M → $227M (+$69.1M)

24% more funds holding

Funds holding: 71 → 88 (+17)

19% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 21

15% more call options, than puts

Call options by funds: $1.82M | Put options by funds: $1.58M

3.03% more ownership

Funds ownership: 40.32% → 43.35% (+3%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
88
Holders Change
+17
Holders Change %
+23.94%
% of All Funds
2.01%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
26
Increased
25
Reduced
21
Closed
9
Calls
$1.82M
Puts
$1.58M
Net Calls
+$241K
Net Calls Change
-$839K

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$12.2M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$4.94M
3
Norges Bank
Norges Bank
Norway
+$3.67M
4
EI
EAM Investors
California
+$3.41M
5
Morgan Stanley
Morgan Stanley
New York
+$2.88M

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$10.7M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$4.07M
3
Goldman Sachs
Goldman Sachs
New York
-$2.61M
4
Renaissance Technologies
Renaissance Technologies
New York
-$2M
5
OAM
Oxford Asset Management
United Kingdom
-$1.78M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$38.6M -$10.7M -1,080,595 -21%
Primecap Management
2
Primecap Management
California
$38.5M +$695K +70,000 +2%
FCMI
3
Foresite Capital Management IV
California
$25.3M +$248K +25,000 +0.9%
BlackRock
4
BlackRock
New York
$22.9M +$309K +31,078 +1%
LTFS
5
Ladenburg Thalmann Financial Services
Florida
$17.1M +$993 +100 +0%
EC
6
EcoR1 Capital
California
$11.6M +$12.2M +1,231,800 New
Morgan Stanley
7
Morgan Stanley
New York
$9.69M +$2.88M +289,556 +39%
Bank of Montreal
8
Bank of Montreal
Ontario, Canada
$8.6M -$343K -34,558 -4%
State Street
9
State Street
Massachusetts
$5.51M +$835K +84,135 +17%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$4.7M +$4.94M +497,328 New
Norges Bank
11
Norges Bank
Norway
$3.49M +$3.67M +369,720 New
EI
12
EAM Investors
California
$3.24M +$3.41M +342,949 New
Northern Trust
13
Northern Trust
Illinois
$3.13M +$350K +35,292 +12%
Vanguard Group
14
Vanguard Group
Pennsylvania
$2.69M +$1.94M +195,542 +220%
Jennison Associates
15
Jennison Associates
New York
$2.55M +$2.68M +269,699 New
Bank of New York Mellon
16
Bank of New York Mellon
New York
$1.81M +$1.08M +108,398 +130%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.75M +$606K +61,017 +49%
SCM
18
Sio Capital Management
New York
$1.56M +$1.64M +164,943 New
Deutsche Bank
19
Deutsche Bank
Germany
$1.54M +$573K +57,731 +55%
Victory Capital Management
20
Victory Capital Management
Texas
$1.43M -$76.1K -7,660 -5%
Hudson Bay Capital Management
21
Hudson Bay Capital Management
Connecticut
$1.42M -$348K -35,000 -19%
EGI
22
EAM Global Investors
California
$1.17M +$1.23M +123,517 New
PPA
23
Parametric Portfolio Associates
Washington
$998K +$1.05M +105,617 New
CS
24
Candriam SCA
Luxembourg
$992K +$1.04M +105,000 New
SG Americas Securities
25
SG Americas Securities
New York
$991K +$1.04M +104,856 New
1
2 3 4

ABUS Hedge Fund Activity: Q3 2018 in Review

88 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2018, worth a combined $227M — up 44% from $158M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ABUS positions and 9 closed out — a net gain of 17 holders — while 25 added to existing stakes and 21 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $12.2M. The largest seller was RTW Investments, cutting an estimated $10.7M.

  • 88 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2018, up from 71 in Q2 2018.
  • Funds reported $227M of Arbutus Biopharma stock for Q3 2018, up 44% quarter-over-quarter.
  • 26 funds opened new Arbutus Biopharma positions in Q3 2018 and 9 closed out, a net change of +17 holders.
  • The largest Arbutus Biopharma buyer in Q3 2018 was EcoR1 Capital, an estimated $12.2M added.
  • The largest Arbutus Biopharma seller in Q3 2018 was RTW Investments, an estimated $10.7M sold.

Based on aggregated 13F filings for Q3 2018.